Immunohistochemical localization of nerve fibers in the pseudocapsule of fibroids

Y. Sun,1 L. Zhu,2 X. Huang,2 C. Zhou,2 X. Zhang2
1Hebei Province General Hospital, Shijiazhuang, Hebei
2Department of Gynecology Women’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Abstract

The pseudocapsule surrounding fibroids consists of compressed myometrium containing nerves and blood vessels that continue into adjacent myometrium. Oxytocin (OXT) is thought to affect wound healing after myomectomy. We determined the presence of OXT and protein gene product 9.5 (PGP9.5) immunoreactive nerve fibers in pseudocapsule compared to adjacent myometrium. Samples (N=106) of pseudocapsule and adjacent myometrium were collected from 57 women with uterine fibroids undergoing myomectomy, and stained with anti-OXT and PGP 9.5 antibodies to demonstrate the presence of nerve fibers. Nerve fibers in the pseudocapsule were stained positively with OXT (89/106, 84.0%) and PGP 9.5 (94/106, 88.7%). The densities of nerve fibers staining with PGP 9.5 and OXT in the pseudocapsule were highest in the isthmus (23.68±22.45/mm2 and 43.35±40.74/mm2, respectively). There were no significant differences in the density of nerve fibers, stained with either OXT or PGP 9.5, between the pseudocapsule, and adjacent normal myometrium regardless of the fibroid location in the uterus (P=0.05). These results suggest that the pseudocapsule should avoid to be damaged during the myomectomy procedure.

Materials and Methods

Patients and samples collection

Between May 2011 and February 2012, a total of 57 non-pregnant women (mean age: 33.6 years; range: 27-42 years) who required to undergo laparoscopic myomectomy at the Women’s Hospital, Zhejiang University School of Medicine, China were recruited in this study. The indications for myomectomy included intractable menorrhagia not responding to conservative treatment, a large uterus associated with urinary or/and rectal symptoms, or uncontrolled growth as verified by repeated ultrasound. The study was approved by the Human Ethics Committee of the Women’s Hospital, School of Medicine, Zhejiang University. All subjects gave their informed consent to participate in the study. All fibroids were diagnosed using standard-ized transvaginal ultrasound myoma mapping by an expert technician, and evaluated under laparoscopy during the surgical procedure (Figures 1 and 2). If the pseudocapsule of uterine fibroids could not be identified under ultrasonography or distinguished from adenomyosis, we further performed a magnetic resonance imaging (MRI) examination. The fibroids were intramural, corporal, fundal, cor- nual and isthmus and the ultrasound data were recorded for postsurgical evaluation. Prior to surgery, pregnancy was excluded by a serum HCG test. Moreover, a history of gynecological tumors, post-treatment of gonadotropin-releasing hormone agonists (GnRHa) and previous uterine scar (including cesarean section) were also excluded. Furthermore, all the participants had no history of endometriosis, adenomyosis or pelvic inflammatory diseases, which was confirmed by laparoscopy. In addi- tion, none of them received sex-hormone therapy prior to surgery.

All uterine fibroids were single or multiple, located in the fundus, the corpus, the cornua or the isthmus, respectively. The diameter of the fibroids was between 3 and 14 cm. In order to obtain adequate samples of the uterine fibroid pseudocapsule and the surrounding normal myometrium, we chose intramural and subserosal fibroids (n. 5 and 4 by Wamsteker classification) as the study subjects.24,25 Pseudocutlated, cervical and intraligamentary fibroids were excluded directly under ultrasonographic examination or during the surgical procedure. All myomectomies were performed by laparoscopic surgery under general

Conflict of interests: the authors declare no conflict of interests.

Contributions: YS, manuscript design and writing; LZ, CZ, immunohistochemical staining; XH, samples collection and statistical analysis.

Immunohistochemistry, oxytocin, myomectomy, protein gene product 9.5, immunohistochemistry.

Keywords: fibroid pseudocapsule, nerve fibers, oxytocin, myomectomy, protein gene product 9.5, immunohistochemistry.

Correspondence: Xinmei Zhang, Department of Gynecology, Women’s Hospital, Zhejiang University School of Medicine, 1 Xueshi Road, Hangzhou, Zhejiang 310006, China. Fax: +86.571.87061378. E-mail: zhangxinm@zju.edu.cn

Received for publication: 26 July 2013. Accepted for publication: 17 March 2014.

This work is licensed under a Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0).
anesthesia with endotracheal intubation, which depends on the dimensions of the fibroid. After surgery, fibroids were confirmed by histopathological examination. All surgical procedures were performed by experienced gynecologists (YMS, XFH and XMZ, three of the authors). The laparoscopic myomectomies were performed using a standardized method as previously described by Malvasi et al. Briefly, incisions were made longitudinally using monopolar or bipolar diathermy until opening the relatively bloodless plane between the pseudocapsule and the fibroid. Once the surface of the fibroid was breached, the fibroid was hooked and extracted from its capsule by traction and pushing down the capsule (Figure 2). The pseudocapsule and the surrounding normal myometrial tissues were excised using scissors during the procedure. The samples were immediately sent to the laboratory in a dry-ice container for histological and immunofluorescent studies.

Histology, immunohistochemistry and immunofluorescence

All samples of the pseudocapsule and the surrounding normal myometrium were fixed in 10% neutral buffered formalin for approximately 18-24 h, processed and embedded in paraffin wax according to a standard protocol. We obtained two sections (cut at 5 μm) from each pseudocapsule or myometrium, such that one section was used for the hematoxylin and eosin staining, and the other for the immunohistochemical staining. For the indirect immunofluorescence analysis, the specimens were frozen in dry ice and sectioned in a cryostat (6 μm thickness). The hematoxylin and eosin staining and the immunohistochemical staining were performed as described previously. Serial sections were cut at 5 μm, and immunostained using polyclonal rabbit anti-PGP9.5 antibody (dilution 1:500, Z5116; Dako Cytomation, Glostrup, Denmark) for 60 min at room temperature. The sections were washed in phosphate-buffered saline (PBS) and incubated with Envision-labeled polymer-alkaline phosphatase mouse/rabbit (EnVision/HRP/Mo, G400105; EnVision/HRP/Rb, G400305/15; Novocastra, Newcastle-upon-Tyne, UK) for 60 min. The antigen-antibody reaction was visualized using diaminobenzidine (DAB) as chromogen (GK346810; Novocastra). After washing, the sections were counterstained with Mayer’s hematoxylin, dehydrated, and mounted with a mounting medium. Normal vulval skin was used as the positive control group. Negative controls were incubated with normal goat serum (X0907; Dako) instead of the primary antibody. The indirect immunofluorescence detection of OXT was performed as described previously. Briefly, after retrieving antigen for oxytocin, the sections were incubated with polyclonal rabbit anti-OXT antibody (dilution 1:100, AB911; Millipore, Germany) for 60 min at room temperature. The sections were washed in PBS and incubated with secondary fluorescein isothiocyanate (FITC)-conjugated swine anti-rabbit IgG antibody (R0156, Dako A/S, Denmark) for 30 min at 37°C in dark. After washing, the sections were observed under fluorescence microscopy (AX-70, Olympus, Tokyo, Japan). All the sections were finally evaluated by an experienced gynecological pathologist who was unaware of the sample background. If no immunoactive nerve fibers appeared on the slides, we defined them as negative cases. Otherwise, we designated them as positive cases and counted the percentage (positive cases/total cases) as well as positive nerve fibers.

Quantification of nerve fiber density

We used a microvascular density quantification method previously described by Weidner with minor modification to count the number of nerve fibers identified by using PGP9.5 staining in the pseudocapsule and the surrounding normal myometrium. After immunostaining, the entire section was scanned at low power (100×) (Leica MZ16 microscope system, Leica Microsystems, Wetzlar, Germany) to identify hot spots, which represent the areas of highest innervation. The individual nerve fibers were then counted at high magnification (400×) to obtain a nerve count in a defined area. The total number of

Figure 1. Serosal fibroid image shown under sonography. A) Transvaginal ultrasound shows a serosal fibroid located in the uterine isthmus. B) Ultrasound image shows the surrounding ring of the fibroid for the pseudocapsule (highlighted by white arrows). C) Doppler ultrasound shows the surrounding ring of fire and vessels for the pseudocapsule.

Figure 2. A serosal uterine fibroid shown by laparoscopy during surgery. A) A serosal fibroid located at the uterine isthmus was shown under laparoscopy. B) A laparoscopic image showing the fibroid and the surrounding pseudocapsule.
nerve fibers was divided by the total number of hot spots on each section to obtain an average of nerve fibers per hot spot (each hot spot measuring 1 mm²). The results were expressed as the mean (±SD) number of nerve fibers/mm² in each specimen from all the samples. The average nerve count in five hot spots was calculated because no significant difference was found in the total number of hot spots between the study groups. A single observer who was blind to the sample background counted the number of PGP9.5-positive nerve fibers.

The chromaticity-positive nerve cells showed green fluorescence under fluorescence microscopy. The density of oxytocin immunoreactive nerve fibers was calculated in 5 randomly selected and homogeneous areas under fluorescence microscopy (200×, Olympus, AX-70). The total number of nerve fibers was divided by the total number of areas on each section to obtain an average of nerve fibers per area (each area measuring 1 mm²). The results were expressed as the mean (±SD) number of nerve fibers/mm² in each specimen from all the samples.

**Statistical analysis**

We used the Statistical Package for the Social Sciences version 13.0 (SPSS, Chicago, IL, USA) to perform statistical analyses. The results were expressed as the mean (±SD) number of nerve fibers/mm² in each specimen from all pseudocapsule and myometrium sections, although the measured values of the variables were not normally distributed. The Mann-Whitney U-test was used to compare the differences in the percentage of immunoreactive nerve fibers between groups. The χ² test was used to compare the differences in the percentage of immunoreactive nerve fibers between groups. The Spearman correlation was used to analyze the correlations between groups. Differences were considered significant at P<0.05.

**Results**

This study included 15 women (26.3%) with single fibroids and 42 (73.7%) with multiple fibroids, which had a mean BMI of 23.8, a mean parity of 1.2, and a mean abortion of 1.8. Fifty-seven women had a total of 106 fibroids. Of the 106 fibroids, 27 fibroids (25.5%) were located in the posterior wall, 25 (23.6%) in the anterior wall, 15 (14.2%) in the lateral wall, 18 (17.0%) in the fundus, 9 (8.5%) in the cornua and 12 (11.3%) in the isthmus of the uterus, respectively (Tables 1 and 2). PGP9.5-immunoreactive nerve fibers were detected in the pseudocapsule in 89/106 fibroids (84.0%). The percentage of PGP9.5-immunoreactive nerve fibers in the fibroid pseudocapsule was different at different sites with the highest percentage in the isthmus (Table 1, Figure 3). In normal myometrium 95/106 (89.6%) stained positive with PGP9.5-immunoreactive nerve fibers. There were no significant differences in the percentage of PGP9.5-immunoreactive nerve fibers between fibroid pseudocapsule and surrounding normal myometrium either in the posterior, anterior, lateral, fundus, cornua or isthmus of the uterus (P>0.05, Table 1).

The density of PGP9.5-immunoreactive nerve fibers in fibroid pseudocapsule was also different at different sites in the uterus with the highest levels in the isthmus (23.68±22.45/mm², P<0.01, versus other sites), and the lowest levels in the fundus (3.08±3.43/mm², P<0.05, versus lateral or isthmus). In the surrounding normal myometrium, PGP9.5-immunoreactive nerve fibers showed similar patterns, as per quantity and quality, to fibroid pseudocapsule. No statistical significant differences with respect to the density of PGP9.5-immunoreactive nerve fibers between the fibroid pseudocapsule and the surrounding normal myometrium either in the posterior, anterior, lateral, fundus, cornua or isthmus of the uterus were found (P>0.05, Table 1). Oxytocin-immunoreactive nerve fibers in the pseudocapsule were detected in 94/106 (88.7%) fibroids. The density of OXT-immunoreactive nerve fibers in the fibroid pseudocapsule was higher in the lateral wall,

### Table 1. Distribution of PGP9.5-immunoreactive nerve fibers in the fibroid pseudocapsule and the normal myometrium (Mean±SD/mm²).

| Location | Number of uterine fibroids | Pseudocapsule Percentage | Myometrium | Pseudocapsule Density | Myometrium |
|----------|---------------------------|--------------------------|------------|----------------------|-----------|
| Anterior | 25                        | 80.0% (20/25)            | 84.0% (21/25) | 5.13±4.11 | 5.21±4.08 |
| Posterior| 27                        | 77.8% (21/27)            | 81.5% (22/27) | 4.76±5.51 | 4.84±5.75 |
| Lateral  | 15                        | 86.7% (13/15)            | 86.7% (13/15) | 11.03±8.13 | 10.98±8.32 |
| Fundus   | 18                        | 88.9% (16/18)            | 100% (18/18)  | 3.08±3.43 | 3.23±3.51 |
| Cornua   | 9                         | 77.8% (7/9)              | 100% (9/9)   | 4.83±4.46 | 4.78±4.89 |
| Isthmus  | 12                        | 100% (12/12)             | 100% (12/12) | 23.68±22.45 | 24.19±23.71 |

### Table 2. Distribution of oxytocin-immunoreactive nerve fibers in the fibroid pseudocapsule and the normal myometrium (Mean±SD/mm²).

| Location | Number of uterine fibroids | Pseudocapsule Percentage | Myometrium | Pseudocapsule Density | Myometrium |
|----------|---------------------------|--------------------------|------------|----------------------|-----------|
| Anterior | 25                        | 80.0% (20/25)            | 92.0% (23/25) | 11.64±11.99 | 11.28±12.57 |
| Posterior| 27                        | 88.9% (24/27)            | 92.6% (25/27) | 15.13±9.97 | 15.41±10.14 |
| Lateral  | 15                        | 100% (15/15)             | 100% (15/15) | 30.15±20.77 | 31.09±25.65 |
| Fundus   | 18                        | 77.8% (14/18)            | 72.2 (13/18)  | 10.08±9.97 | 9.96±10.52 |
| Cornua   | 9                         | 100% (9/9)               | 100% (9/9)   | 28.23±19.06 | 28.61±22.17 |
| Isthmus  | 12                        | 100% (12/12)             | 100% (12/12) | 43.35±40.74 | 40.97±44.23 |
cornu and isthmus of the uterus, yet the differences at different sites of the uterus did not reach statistical significance (P>0.05, Table 2, Figure 4). Normal myometrium showed similar distribution of OXT-immunoreactive nerve fibers to fibroid pseudocapsule. No significant differences were detected in OXT-immunoreactive nerve fibers between the fibroid pseudocapsule and surrounding normal myometrium at different sites in the uterus (P>0.05, Table 2). The density of OXT-immunoreactive nerve fibers in the fibroid pseudocapsule was also different at different sites in the uterus with the lowest levels in the fundus (10.08±9.97/mm², P<0.01, versus lateral, cornua or isthmus), and the highest in the isthmus (43.35±40.74/mm², P<0.01, versus other sites; Table 2). The normal myometrium exhibited the same distribution of OXT-immunoreactive nerve fibers as fibroid pseudocapsule. The density of OXT-immunoreactive nerve fibers were similar in the fibroid pseudocapsule and the normal myometrium either in the posterior, anterior, lateral, fundus, cornua or isthmus of the uterus (P>0.05, Table 2).

Discussion

Nerve fibers staining with PGP9.5 are present in similar quantities in the pseudocapsule of uterine fibroids, and adjacent normal myometrium no matter where the fibroids are located in the uterus. Our results also showed that oxytocin-immunoreactive nerve fibers are also present in the pseudocapsule and adjacent normal myometrium, and both showed similar patterns of distribution. The densities of nerve fibers stained with PGP9.5 and oxytocin were both highest in the isthmus, and then in the lateral wall of the uterus. PGP9.5 is a pan-neural marker labeling autonomic nerve fibers and also sensory nerve fibers. PGP9.5-immunoreactive nerve fibers may be involved in the pathophysiology of uterine fibroids, and affect muscle contractility, uterine peristalsis and muscular healing. Since pseudocapsule is a neurovascular bundle or fibrovascular network surrounding the fibroids, damaging the pseudocapsule during the myomectomy procedure may affect reinnervation and revascularization of the uterine incision. As a neuromodulator, oxytocin has been shown to be involved in a variety of biological processes, not only enhancing uterine contractility, and modulating pain trigger and social behavior, but also possessing antiinflammatory, antioxidative stress and tumorigenic properties. Oxytocin exerts its biological functions by binding its receptor. The abnormality of OXTR expression and abnormal response of OXTR to OXT may cause abnormal uterine contractility, leading to infertility or preterm birth. Oxytocin or OXTR antagonists are believed to improve infertility treatment. Obviously, oxytocin-immunoreactive nerve fibers in the pseudocapsule may play a role in the mechanisms of uterine fibroids and also influence on uterine muscle contractility and wound healing as well as future fertility after myomectomy if the pseudocapsule of uterine fibroids was damaged during the surgical procedure.

The pseudocapsule is a neurovascular bundle that separates fibroids from the adjacent normal myometrium. Besides PGP9.5 and oxytocin immunoreactive nerve fibers in the pseudocapsule in our study, other nerve fibers such as neurotensin-, neuropeptide- tyrosine-, substance P- and vasoactive intestinal peptide-immunoreactive nerve fibers were also present in the pseudocapsule. Interestingly, all these nerve fibers showed similar patterns of distribution in the pseudocapsule and the adjacent normal myometrium. However, all these studies including ours did not investigate the correlation between fibroid pseudocapsule thickness and the density of nerve fibers. Therefore, further studies with additional neural markers with different sites will be necessary to confirm or refute the role of nerves in the etiology of some patterns of fibroids.

References

1. Nishiyama S, Saito M, Sato K, Kurishita M, Itasaka T, Shioda K. High recurrence rate of uterine fibroids on transvaginal ultrasound after abdominal myomectomy in Japanese women. Gynecol Obstet Invest 2006;61:155-9.
2. Tinelli A, Hurst BS, Hudelist G, Tsin DA,
Stark M, Mettler L, et al. Laparoscopic myomectomy focusing on the myoma pseudocapsule: technical and outcome reports. Hum Reprod 2012;27:427-35.

3. Quinn M. Uterine innervation in fibroids: a qualitative study. J Obstet Gynaecol 2007;27:489-92.

4. Malvasi A, Cavallotti C, Nicolardi G, Pellegrino M, Dell’Edera D, Vergara D, et al. NT, NPY and PGP 9.5 presence in myometrium and in fibroid pseudocapsule and their possible impact on muscular physiology. Gynecol Endocrinol 2013;29:177-81.

5. Malvasi A, Tinelli A, Cavallotti C, Morrone M, Tsin DA, Nezhat C, et al. Distribution of substance P (SP) and vasoactive intestinal peptide (VIP) in pseudocapsules of uterine fibroids. Peptides 2011;32:327-32.

6. Tinelli A, Malvasi A, Hurst BS, Tsin DA, Davila F, Dominguez G, et al. Surgical management of neurovascular bundle in uterine fibroid pseudocapsule. JSLS 2012;16:119-29.

7. Tinelli A, Malvasi A, Cavallotti C, Dell’Edera D, Tsin DA, Stark M, et al. The management of fibroids based on immunohistochemical studies of their pseudocapsules. Expert Opin Ther Targets 2011;15:1241-7.

8. Malvasi A, Cavallotti C, Morrone M, Lorenzi T, Dell’Edera D, Nicolardi G, et al. Uterine fibroid pseudocapsule studied by transmission electron microscopy. Eur J Obstet Gynecol Reprod Biol 2012;162:187-91.

9. Lee HJ, Macbeth AH, Pagani JH, Young WS 3rd. Oxytocin: the great facilitator of life. Prog Neurobiol 2009;88:827-51.

10. Veenema AH, Neumann ID. Central vasoressin and oxytocin release: regulation of complex social behaviours. Prog Brain Res 2008;170:261-76.

11. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev 2001;81:629-83.

12. Iweli R, Kimura T, Muller D, Augustin K, Abend N, Bathgate R, et al. The structure and regulation of the oxytocin receptor. Exp Physiol 2001;86:289-96.

13. Zingg HH, Laporte SA. The oxytocin receptor. Trends Endocrinol Metab 2003;14:222-7.

14. Biyikli NK, Tugtepe H, Sener G, Velioglu-Ogüç A, Cetinel S, Midilligloğlu S, et al. Oxytocin alleviates oxidative renal injury in pyelonephritic rats via a neutrophil-dependent mechanism. Peptides 2006;27:2249-57.

15. Szeto A, Nation DA, Mendez AJ, Dominguez-Bendala J, Brooks LG, Schneiderman N, et al. Oxytocin attenuates NADPH-dependent superoxide activity and IL-6 secretion in macrophages and vascular cells. Am J Physiol Endocrinol Metab 2008;295:E1495-501.

16. Dery MC, Chaudhry P, Leblanc V, Parent S, Fortier AM, Asselin E. Oxytocin increases invasive properties of endometrial cancer cells through phosphatidylinositol 3-kinase/AKT-dependent up-regulation of cyclooxygenase-1, -2, and X-linked inhibitor of apoptosis protein. Biol Reprod 2011;85:1133-42.

17. Ebstein RP, Knafo A, Mankuta D, Chew SH, Lai PS. The contributions of oxytocin and vasopressin pathway genes to human behavior. Horm Biol 2012;37:121-45.

18. Gouin JP, Carter CS, Pournajafi-Nazarloo H, Glaser R, Malarkey WB, Laven J, et al. Marital behavior, oxytocin, vasopressin, and wound healing. Psychoneuroendocrinology 2010;35:1082-90.

19. Klein BY, Tamir H, Hirschberg DL, Glickstein SB, Welch MG. Oxytocin modulates mTORC1 pathway in the gut. Biochem Biophys Res Commun 2013;432:466-71.

20. Lundberg LM, Alm P, Wharton J, Polak JM. Protein gene product 9.5 (PGP 9.5). A new neuronal marker visualizing the whole uterine innervation and pregnancy-induced and developmental changes in the guinea pig. Histochemistry 1988;90:9-17.

21. Dalsgaard CJ, Rydh M, Haegerstrand A. Cutaneous innervation in man visualized with protein gene product 9.5 (PGP 9.5) antibodies. Histochemistry 1989:92:385-90.

22. Wang L, Hilliges M, Jernberg T, Wiegeln-Eiström D, Johansson O. Protein gene product 9.5-immunoreactive nerve fibres and cells in human skin. Cell Tissue Res 1990;261:25-33.

23. Wilson PO, Barber PC, Hamid QA, Power BF, Dhillon AP, Rode J, et al. The immunolocalization of protein gene product 9.5 using rabbit polyclonal and mouse monoclonal antibodies. Br J Exp Pathol 1988;69:91-104.

24. Munro MG, Critchley HO, Broder MS, Fraser IS; FIGO Working Group on Menstrual Disorders. FIGO classification system for Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet 2011;113:3-13.

25. Lasmar RB, Xinmei Z, Indman PD, Celeste RR, Di Spiezo Sardo A. Feasibility of a new system of classification of submucous myomas: a multicenter study. Fertil Steril 2011;95:2073-7.

26. Ohlsson B, Truedsson M, Djerf P, Sundler F. Oxytocin is expressed throughout the human gastrointestinal tract. Regul Pept 2006;135:7-11.

27. Zhang X, Lu B, Huang X, Xu H, Zhou C, Lin J. Innervation of endometrium and myometrium in women with painful adenomyosis and uterine fibroids. Fertil Steril 2010;94:730-7.

28. Benaroch EE. Oxytocin and vasopressin: social neuropeptides with complex neuro-modulatory functions. Neurology 2013;80:1521-8.

29. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995;36:169-80.

30. Wang YL, Yuan Y, Yang J, Wang CH, Pan YJ, Lu L, et al. The interaction between the oxytocin and pain modulation in headache patients. Neuropeptides 2013;47:93-7.

31. Guo SW, Mao X, Ma Q, Liu X. Dysmenorrhea and its severity are associated with increased uterine contractility and overexpression of oxytocin receptor (OTR) in women with symptomatic adenomyosis. Fertil Steril 2013;99:231-40.

32. Turton P, Neilson JP, Quenby S, Burdya T, Wray S. A short review of twin pregnancy and how oxytocin receptor expression may differ in multiple pregnancies. Eur J Obstet Gynecol Reprod Biol 2009;144:540-4.

33. Kuesel L, Grimm C, Knöfler M, Haslinger RK, Di Spiezio Sardo A. Feasibility of a new system of classification of submucous myomas. Obstet Gynecol 2011;117:e19-22.

34. Moszkowicz D, Alsaid B, Bessede T, Penna C, Benoit G, Peschaud F. Female pelvic autonomic neuroanatomy based on conventional macroscopic and computer-assisted anatomic dissections. Surg Radiol Anat 2011;33:397-404.

35. Pierzynski P, Reinheimer TM, Kuczyński W. Oxytocin antagonists may improve infertility treatment. Fertil Steril 2007;88:213.e19-22.

[page 162] [European Journal of Histochemistry 2014; 58:2249]